Pharmacokinetic animal PET study of FK506 as a potent neuroprotective agent

Journal of Nuclear Medicine

Volumn 45, Issue 11, 2004, Pages 1946-1949

  Murakami, Yoshihiro ^a,b,c,d   Takamatsu, Hiroyuki ^a,b   Noda, Akihiro ^a,b   Osoda, Kazuhiko ^a,b   Ichise, Rikiya ^a   Tatsumi, Mitsuyoshi ^a   Tabata, Kenji ^b   Sawamoto, Taiji ^b   Nishimura, Shintaro ^a,b  

^a Medical and Pharmacological Research Center Foundation   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

^d Medical and Pharmacological Research Center Foundation   (Japan)

Author keywords

Brain concentration; FK506; Monkey; Neuroprotectant; PET; Stroke

Indexed keywords

RADIOPHARMACEUTICAL AGENT; TACROLIMUS; TACROLIMUS C 11; UNCLASSIFIED DRUG; CARBON; DIAGNOSTIC AGENT; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; MACACA; MALE; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RELATIVE DENSITY; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; BRAIN; DRUG SCREENING; EVALUATION; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; CARBON RADIOISOTOPES; DRUG EVALUATION, PRECLINICAL; MACACA FASCICULARIS; MALE; METABOLIC CLEARANCE RATE; NEUROPROTECTIVE AGENTS; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; TACROLIMUS; TISSUE DISTRIBUTION;

EID: 16544375117     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Kidwell CS, Liebeskind DS, Starkman S, Saver JL. Trends in acute ischemic stroke trials through the 20th century. Stroke. 2001;32:1349-1359.
2. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 2002;33:2123-2136.
3. Sharkey J, Butcher SP. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature. 1994;371:336-339.
4. Maeda M, Furuichi Y, Ueyama N, et al. A combined treatment with tacrolimus (FK506) and recombinant tissue plasminogen activator for thrombotic focal cerebral ischemia in rats: increased neuroprotective efficacy and extended therapeutic time window. J Cereb Blood Flow Metab. 2002;22:1205-1211.
5. Butcher SP, Henshall DC, Teramura Y, Iwasaki K, Sharkey J. Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism. J Neurosci. 1997;17:6939-6946.
6. Furuichi Y, Katsuta K, Maeda M, et al. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res. 2003;965:137-145.
7. Takamatsu H, Tsukada H, Noda A, et al. FK506 attenuates early ischemic neuronal death in a monkey model of stroke. J Nucl Med. 2001;42:1833-1840.
8. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077-6080.
9. 11C-labeled FK506 for positron emission tomography. Tetrahedron Lett. 2003;44:641-644.
10. Watanabe M, Okada H, Shimizu K, et al. A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans Nucl Sci. 1997;44:1277-1282.
11. Cross DJ, Minoshima S, Nishimura S, Noda A, Tsukada H, Kuhl DE. Three-dimensional stereotactic surface projection analysis of macaque brain PET: development and initial applications. J Nucl Med. 2000;41:1879-1887.
12. Tamura K, Kobayashi M, Hashimoto K, et al. A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc. 1987;19:23-29.